Prof. Mike’s Health Corner

Could a common diabetes drug offer protection against COVID-19?

By MICHAEL KOSSOVE
Posted 11/18/26

A medication taken by millions of people with Type 2 diabetes may have another potential benefit: reducing certain complications associated with COVID-19. The medication is metformin, one of the …

This item is available in full to subscribers.

Please log in to continue

Log in
Prof. Mike’s Health Corner

Could a common diabetes drug offer protection against COVID-19?

Posted

A medication taken by millions of people with Type 2 diabetes may have another potential benefit: reducing certain complications associated with COVID-19. The medication is metformin, one of the oldest and most widely prescribed drugs for controlling blood sugar.

Researchers have been investigating whether metformin might do more than regulate glucose. Laboratory studies suggest that it may interfere with the ability of viruses to reproduce inside human cells. It also appears to influence inflammatory processes that play a role in the body's response to infection.

One particularly interesting study, published in The Lancet Infectious Diseases in 2023, involved more than 1,100 adults who had tested positive for COVID-19. Participants received either metformin or a placebo shortly after developing symptoms.

The results attracted considerable attention. Approximately 6.3 percent of those receiving metformin developed long COVID, compared with 10.4 percent of those receiving the placebo. This represented an approximately 41 percent reduction in relative risk.

Long COVID can involve persistent fatigue, breathing difficulties, memory problems, muscle pain and other symptoms that continue long after the initial infection has disappeared.

Additional research published in 2024 found that metformin was associated with a reduction in SARS-CoV-2 viral levels in infected individuals. This provided another possible explanation for its beneficial effects.

But there is an important distinction that consumers should understand. These findings do not establish that people taking metformin for diabetes are protected against becoming infected with COVID-19 in the first place. Some earlier observational studies suggested a lower infection rate among metformin users, but observational findings cannot establish cause and effect.

A 2025 systematic review of randomized clinical trials also concluded that evidence for preventing serious acute COVID-19 outcomes remains uncertain, although metformin may reduce the likelihood of developing Long COVID.

So, what does this mean for people with diabetes?

Metformin remains an important medication for controlling Type 2 diabetes. Its possible additional benefits against COVID-19 are encouraging and deserve further investigation. However, nobody should begin taking metformin, increase their dosage, or change their existing diabetes treatment in an attempt to prevent COVID-19 without consulting a physician.

The lesson is that medical research continues to uncover unexpected benefits from familiar medications. Sometimes, an old drug may offer new possibilities. But promising research is not the same as proven protection.

COVID-19, metformin, diabetes, drugs, long COVID

Comments

No comments on this item Please log in to comment by clicking here